Cirrhotic cardiomyopathy: Pathogenesis and clinical relevance

Nature Reviews Gastroenterology and Hepatology

Volumn 11, Issue 3, 2014, Pages 177-186

  Wiese, Signe ^a   Hove, Jens D ^b   Bendtsen, Flemming ^a   Møller, Søren ^a  

^a Centre for Functional Imaging and Research Department of Clinical Physiology and Nuclear Medicine   (Denmark)

^b Gastroenterology Unit Medical Division   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIURETIC AGENT; SODIUM; SPIRONOLACTONE; TROPONIN I; TROPONIN T;

CARDIOMYOPATHY; CIRRHOTIC CARDIOMYOPATHY; CLINICAL ASSESSMENT; CLINICAL FEATURE; DIASTOLIC DYSFUNCTION; DILUTIONAL HYPONATRAEMIA; ECHOCARDIOGRAPHY; ESOPHAGUS VARICES BLEEDING; EXPERIMENTAL MODEL; HEART HEMODYNAMICS; HEPATIC NEPHROPATHY; HUMAN; HYPONATREMIA; KIDNEY FUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TRANSPLANTATION; LUNG VENTILATION PERFUSION RATIO; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATHOPHYSIOLOGY; PORTOPULMONARY HYPERTENSION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QT PROLONGATION; RADIOCARDIOGRAPHY; REVIEW; AUTONOMIC DYSFUNCTION; CARDIOVASCULAR MAGNETIC RESONANCE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE MODEL; EXERCISE TEST; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONTRACTILITY; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; KIDNEY DISEASE; MEDICAL ASSESSMENT; PHARMACOLOGIC STRESS TESTING; PORTAL HYPERTENSION; REST; SYSTOLIC DYSFUNCTION; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;

CARDIOMYOPATHIES; HEMODYNAMICS; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PROGNOSIS;

EID: 84895918503     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2013.210     Document Type: Review

References (116)

1. Kowalsky, H. J. & Belmann, W. H. The cardiac output at rest in Laennec's cirrhosis. J. Clin. Invest. 32, 1025-1033 (1953).
2. Møller, S. & Henriksen, J. H. Cardiovascular complications of cirrhosis. Gut 57, 268-278 (2008).
3. Møller, S. & Henriksen, J. H. in Ascites and Renal Dysfunction in Liver Disease (eds Gines, P., Arroyo, V., Rodes, J. & Schrier, R. W.), 139-155 (Wiley-Blackwell, 2005).
4. Møller, S., Iversen, J. S., Henriksen, J. H. & Bendtsen, F. Reduced baroreflex sensitivity in alcoholic cirrhosis: relations to hemodynamics and humoral systems. Am. J. Physiol. Heart Circ. Physiol. 292, H2966-H2972 (2007).
5. Fouad, T. R., Abdel-Razek, W. M., Burak, K. W., Bain, V. G. & Lee, S. S. Prediction of cardiac complications after liver transplantation. Transplantation 87, 763-770 (2009).
6. Myers, R. P. & Lee, S. S. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl. 4 (Suppl. 1), S44-S52 (2000).
7. Ortiz-Olvera, N. X. et al. Anatomical cardiac alterations in liver cirrhosis: an autopsy study. Ann. Hepatol. 10, 321-326 (2011).
8. Liu, H. & Lee, S. S. Acute-on-chronic liver failure: the heart and systemic hemodynamics. Curr. Opin. Crit. Care 17, 190-194 (2011).
9. Møller, S. & Henriksen, J. H. Cirrhotic cardiomyopathy. J. Hepatol. 53, 179-190 (2010).
10. Timoh, T., Protano, M. A., Wagman, G., Bloom, M. & Vittorio, T. J. A perspective on cirrhotic cardiomyopathy. Transplant. Proc. 43, 1649-1653 (2011).
11. Kazankov, K. et al. Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging. Liver Int. 31, 534-540 (2011).
12. Nazar, A. et al. Left ventricular function assessed by echocardiography in cirrhosis: relationship to systemic hemodynamics and renal dysfunction. J. Hepatol. 58, 51-57 (2013).
13. Cazzaniga, M. et al. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut 56, 869-875 (2007).
14. Jones, D. E. et al. Impaired cardiovascular function in primary biliary cirrhosis. Am. J. Physiol. Gastrointest. Liver Physiol. 298, G764-G773 (2010).
15. Saner, F. H. et al. High brain-natriuretic peptide level predicts cirrhotic cardiomyopathy in liver transplant patients. Transpl. Int. 24, 425-432 (2011).
16. Krag, A., Bendtsen, F., Henriksen, J. H. & Møller, S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 59, 105-110 (2010).
17. Ruiz-del-Arbol, L. et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 42, 439-447 (2005).
18. Rabie, R. N., Cazzaniga, M., Salerno, F. & Wong, F. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am. J. Gastroenterol. 104, 2458-2466 (2009).
19. Møller, S., Hobolth, L., Winkler, C., Bendtsen, F. & Christensen, E. Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis. Gut 60, 1254-1259 (2011).
20. Laleman, W., Landeghem, L., Wilmer, A., Fevery, J. & Nevens, F. Portal hypertension: from pathophysiology to clinical practice. Liver Int. 25, 1079-1090 (2005).
21. Martin, P. Y., Gines, P. & Schrier, R. W. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N. Engl. J. Med. 339, 533-541 (1998).
22. Sola, E. et al. Plasma copeptin levels are increased in cirrhosis and correlate with hyponatremia and circulatory dysfunction. J. Hepatol. 58 (Suppl. 1), 246-247 (2013).
23. Moreno, J. P. et al. Plasma copeptin, a possible prognostic marker in cirrhosis. Liver Int. 33, 843-851 (2013).
24. Lagi, A. et al. Impaired sympathetic regulation of cerebral blood flow in patients with cirrhosis of the liver. Clin. Sci. (Lond.) 103, 43-51 (2002).
25. Møller, S., Krag, A., Madsen, J. L., Henriksen, J. H. & Bendtsen, F. Pulmonary dysfunction and hepatopulmonary syndrome in cirrhosis and portal hypertension. Liver Int. 29, 1528-1537 (2009).
26. Møller, S. & Krag, A. in Hyponatremia and Hepatorenal Syndrome: Progress in Treatment (ed. Gerbes, A.) 102-111 (Karger, Basel, 2011).
27. Arroyo, V., Terra, C. & Gines, P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J. Hepatol. 46, 935-946 (2007).
28. Arroyo, V. et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 23, 164-176 (1996).
29. D'Amico, G., Morabito, A., Pagliaro, L. & Marubini, E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig. Dis. Sci. 31, 468-475 (1986).
30. Gines, P. et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 7, 122-128 (1987).
31. Garcia-Tsao, G. et al. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 5, 419-424 (1985).
32. Bismuth, M., Funakoshi, N., Cadranel, J. F. & Blanc, P. Hepatic encephalopathy: from pathophysiology to therapeutic management. Eur. J. Gastroenterol. Hepatol. 23, 8-22 (2011).
33. Fallon, M. B. & Abrams, G. A. Pulmonary dysfunction in chronic liver disease. Hepatology 32, 859-865 (2000).
34. Rodriguez-Roisin, R., Agusti, A. G. & Roca, J. The hepatopulmonary syndrome: new name, old complexities. Thorax 47, 897-902 (1992).
35. Gerbes, A. L., Remien, J., Jungst, D., Sauerbruch, T. & Paumgartner, G. Evidence for down-regulation of β-2-adrenoceptors in cirrhotic patients with severe ascites. Lancet 1, 1409-1411 (1986).
36. Lee, S. S. et al. Desensitization of myocardial β-adrenergic receptors in cirrhotic rats. Hepatology 12, 481-485 (1990).
37. Ward, C. A., Liu, H. & Lee, S. S. Altered cellular calcium regulatory systems in a rat model of cirrhotic cardiomyopathy. Gastroenterology 121, 1209-1218 (2001).
38. Bortoluzzi, A. et al. Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms. Hepatology 57, 266-276 (2013).
39. Liu, L., Liu, H., Nam, S. W. & Lee, S. S. Protective effects of erythropoietin on cirrhotic cardiomyopathy in rats. Dig. Liver Dis. 44, 1012-1017 (2012).
40. van Obbergh, L., Vallieres, Y. & Blaise, G. Cardiac modifications occurring in the ascitic rat with biliary cirrhosis are nitric oxide related. J. Hepatol. 24, 747-752 (1996).
41. Liu, H. et al. Cardiac thick-filament sturctural and functional changes contribute to cirrhotic cardiomyopathy in rats. J. Hepatol. 58 (Suppl. 1), 240 (2013).
42. Finucci, G. et al. Left ventricular diastolic function in liver cirrhosis. Scand. J. Gastroenterol. 31, 279-284 (1996).
43. Pozzi, M. et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 26, 1131-1137 (1997).
44. Nagueh, S. F. et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J. Am. Soc. Echocardiogr. 22, 107-133 (2009).
45. Kasner, M. et al. Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction: a comparative Doppler-conductance catheterization study. Circulation 116, 637-647 (2007).
46. Oki, T. et al. Clinical application of pulsed Doppler tissue imaging for assessing abnormal left ventricular relaxation. Am. J. Cardiol. 79, 921-928 (1997).
47. Ommen, S. R. et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study. Circulation 102, 1788-1794 (2000).
48. Mor-Avi, V. et al. Real-time 3D echocardiographic quantification of left atrial volume: multicenter study for validation with CMR. JACC Cardiovasc. Imaging 5, 769-777 (2012).
49. Poulsen, S. H., Andersen, N. H., Heickendorff, L. & Mogensen, C. E. Relation between plasma amino-terminal propeptide of procollagen type III and left ventricular longitudinal strain in essential hypertension. Heart 91, 624-629 (2005).
50. Ersboll, M. et al. Prediction of all-cause mortality and heart failure admissions from global left ventricular longitudinal strain in patients with acute myocardial infarction and preserved left ventricular ejection fraction. J. Am. Coll. Cardiol. 61, 2365-2373 (2013).
51. Park, T. H. et al. Impact of myocardial structure and function postinfarction on diastolic strain measurements: implications for assessment of myocardial viability. Am. J. Physiol. Heart Circ. Physiol. 290, H724-H731 (2006).
52. Lima, J. A. & Desai, M. Y. Cardiovascular magnetic resonance imaging: current and emerging applications. J. Am. Coll. Cardiol. 44, 1164-1171 (2004).
53. Lawton, J. S. et al. Magnetic resonance imaging detects significant sex differences in human myocardial strain. Biomed. Eng. Online 10, 76 (2011).
54. Zagrosek, A. et al. Cardiac magnetic resonance monitors reversible and irreversible myocardial injury in myocarditis. JACC Cardiovasc. Imaging 2, 131-138 (2009).
55. Iles, L. et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J. Am. Coll. Cardiol. 52, 1574-1580 (2008).
56. Desai, M. S. et al. Hypertrophic cardiomyopathy and dysregulation of cardiac energetics in a mouse model of biliary fibrosis. Hepatology 51, 2097-2107 (2010).
57. Kovacs, A., Schepke, M., Heller, J., Schild, H. H. & Flacke, S. Short-term effects of transjugular intrahepatic shunt on cardiac function assessed by cardiac MRI: preliminary results. Cardiovasc. Intervent. Radiol. 33, 290-296 (2010).
58. Krag, A., Bendtsen, F., Kjær, A., Leth-Petersen, C. & Møller, S. Cardiac function studied by dobutamin stress MRI in patients with mild cirrhosis. J. Hepatol. 50, S277 (2009).
59. Lossnitzer, D. et al. Myocardial late gadolinium enhancement cardiovascular magnetic resonance in patients with cirrhosis. J. Cardiovasc. Magn. Reson. 12, 47 (2010).
60. Møller, S., Søndergaard, L., Møgelvang, J., Henriksen, O. & Henriksen, J. H. Decreased right heart blood volume determined by magnetic resonance imaging: evidence of central underfilling in cirrhosis. Hepatology 22, 472-478 (1995).
61. Wong, F. Cirrhotic cardiomyopathy. Hepatol. Int. 3, 294-304 (2009).
62. Sampaio, F. et al. Systolic and diastolic dysfunction in cirrhosis: a tissue-Doppler and speckle tracking echocardiography study. Liver Int. 33, 1158-1165 (2013).
63. Henriksen, J. H. et al. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 52, 1511-1517 (2003).
64. Ruffa, L., Calicchia, A., Pergolini, A. et al. Cirrhotic cardiomyopathy evaluated with tissue Doppler imaging is not associated with the severity of liver dysfunction in liver cirrhosis. Gut 60 (Suppl. 3), 241 (2011).
65. Wong, F., Villamil, A., Merli, M. et al. Prevalence of diastolic dysfunction in cirrhosis and its clinical significance. Hepatology 54, 475A (2011).
66. Møller, S. & Henriksen, J. H. Cardiovascular dysfunction in cirrhosis. Pathophysiological evidence of a cirrhotic cardiomyopathy. Scand. J. Gastroenterol. 36, 785-794 (2001).
67. Wong, F. et al. The cardiac response to exercise in cirrhosis. Gut 49, 268-275 (2001).
68. Krag, A., Bendtsen, F., Mortensen, C., Henriksen, J. H. & Møller, S. Effects of a single terlipressin administration on cardiac function and perfusion in cirrhosis. Eur. J. Gastroenterol. Hepatol. 22, 1085-1092 (2010).
69. Limas, C. J., Guiha, N. H., Lekagul, O. & Cohn, J. N. Impaired left ventricular function in alcoholic cirrhosis with ascites. Ineffectiveness of ouabain. Circulation 49, 754-760 (1974).
70. Pouriki, S. et al. Left ventricle enlargement and increased systolic velocity in the mitral valve are indirect markers of the hepatopulmonary syndrome. Liver Int. 31, 1388-1394 (2011).
71. Liu, H., Gaskari, S. A. & Lee, S. S. Cardiac and vascular changes in cirrhosis: pathogenic mechanisms. World J. Gastroenterol. 12, 837-842 (2006).
72. De, B. K. et al. Cardiac dysfunction in portal hypertension among patients with cirrhosis and non-cirrhotic portal fibrosis. J. Hepatol. 39, 315-319 (2003).
73. Raizada, V., Skipper, B., Luo, W. & Griffith, J. Intracardiac and intrarenal renin-angiotensin systems: mechanisms of cardiovascular and renal effects. J. Investig. Med. 55, 341-359 (2007).
74. Wong, F., Liu, P., Lilly, L., Bomzon, A. & Blendis, L. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin. Sci. (Lond.) 97, 259-267 (1999).
75. Holt, E. et al. Diastolic dysfunction defined by E/A ratio <1 on 2-D echo is an independent predictor of liver transplantation or death in patients with cirrhosis. J. Hepatol. 54 (Suppl. 1) 245-246 (2011).
76. Ruiz-del-Arbol, L. et al. Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension and a normal creatinine. Hepatology http://dx.doi.org/10.1002/hep.26509.
77. Torregrosa, M. et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J. Hepatol. 42, 68-74 (2005).
78. McDonagh, T. A. et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 351, 9-13 (1998).
79. Levin, E. R., Gardner, D. G. & Samson, W. K. Natriuretic peptides. N. Engl. J. Med. 339, 321-328 (1998).
80. Nageh, T., Sherwood, R. A., Harris, B. M., Byrne, J. A. & Thomas, M. R. Cardiac troponin T and I and creatine kinase-MB as markers of myocardial injury and predictors of outcome following percutaneous coronary intervention. Int. J. Cardiol. 92, 285-293 (2003).
81. Pateron, D. et al. Elevated circulating cardiac troponin I in patients with cirrhosis. Hepatology 29, 640-643 (1999).
82. Wiese, S. et al. Markers of inflammation and cardiac dysfunction are associated with the hemodynamic derangement and prognosis in patients with cirrhosis. Hepatology 56 (Suppl. 1), 162A (2012).
83. Boomsma, F. & van den Meiracker, A. H. Plasma A-and B-type natriuretic peptides: physiology, methodology and clinical use. Cardiovasc. Res. 51, 442-449 (2001).
84. Gottlieb, S. S., Kukin, M. L., Ahern, D. & Packer, M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J. Am. Coll. Cardiol. 13, 1534-1539 (1989).
85. Potter, L. R., Yoder, A. R., Flora, D. R., Antos, L. K. & Dickey, D. M. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb. Exp. Pharmacol. 191, 341-366 (2009).
86. Masson, S. et al. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur. J. Heart Fail. 12, 338-347 (2010).
87. McKie, P. M. et al. Predictive utility of atrial, N.-terminal pro-atrial, and N.-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study. Mayo Clin. Proc. 86, 1154-1160 (2011).
88. Miller, W. L. et al. Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure. Heart 98, 389-394 (2012).
89. Ates, F. et al. The relationship of heart rate variability with severity and prognosis of cirrhosis. Dig. Dis. Sci. 51, 1614-1618 (2006).
90. Newton, J. L., Allen, J., Kerr, S. & Jones, D. E. Reduced heart rate variability and baroreflex sensitivity in primary biliary cirrhosis. Liver Int. 26, 197-202 (2006).
91. Ruiz-del-Arbol, L. et al. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 113, 579-586 (1997).
92. Ruiz-del-Arbol, L. et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 38, 1210-1218 (2003).
93. Song, J. G., Kim, Y. K., Shin, W. J. & Hwang, G. S. Changes in cardiovagal baroreflex sensitivity are related to increased ventricular mass in patients with liver cirrhosis. Circ. J. 76, 2807-2813 (2012).
94. Møller, S. et al. Cardiac sympathetic imaging with mIBG in cirrhosis and portal hypertension: relation to autonomic and cardiac function. Am. J. Physiol. Gastrointest. Liver Physiol. 303, G1228-G1235 (2012).
95. Bernardi, M., Maggioli, C., Dibra, V. & Zaccherini, G. QT interval prolongation in liver cirrhosis: innocent bystander or serious threat? Expert. Rev. Gastroenterol. Hepatol. 6, 57-66 (2012).
96. Lazzeri, C. et al. Autonomic regulation of heart rate and QT interval in nonalcoholic cirrhosis with ascites. Digestion 58, 580-586 (1997).
97. Bernardi, M. et al. Reduced cardiovascular responsiveness to exercise-induced sympathoadrenergic stimulation in patients with cirrhosis. J. Hepatol. 12, 207-216 (1991).
98. Henriksen, J. H., Fuglsang, S., Bendtsen, F., Christensen, E. & Møller, S. Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J. Hepatol. 36, 513-520 (2002).
99. C) in patients with cirrhosis: relation to vasoactive peptides and heart rate. Scand. J. Clin. Lab. Invest. 67, 643-653 (2007).
100. Genovesi, S. et al. QT interval prolongation and decreased heart rate variability in cirrhotic patients: relevance of hepatic venous pressure gradient and serum calcium. Clin. Sci. (Lond.) 116, 851-859 (2009).
101. Trevisani, F. et al. QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. J. Hepatol. 38, 461-467 (2003).
102. Day, C. P., James, O. F., Butler, T. J. & Campbell, R. W. QT prolongation and sudden cardiac death in patients with alcoholic liver disease. Lancet 341, 1423-1428 (1993).
103. Bernardi, M. et al. QT interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 27, 28-34 (1998).
104. Bal, J. S. & Thuluvath, P. J. Prolongation of QTc interval: relationship with etiology and severity of liver disease, mortality and liver transplantation. Liver Int. 23, 243-248 (2003).
105. Arroyo, V., Guevara, M. & Gines, P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 122, 1658-1676 (2002).
106. Krag, A., Bendtsen, F., Burroughs, A. K. & Møller, S. The cardiorenal link in advanced cirrhosis. Med. Hypotheses 79, 53-55 (2012).
107. Gines, P. et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 123, 1839-1847 (2002).
108. Merli, M. et al. Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am. J. Gastroenterol. 97, 142-148 (2002).
109. Ripoll, C. et al. Cardiac dysfunction during liver transplantation: incidence and preoperative predictors. Transplantation 85, 1766-1772 (2008).
110. Therapondos, G. et al. Cardiac function after orthotopic liver transplantation and the effects of immunosuppression: a prospective randomized trial comparing cyclosporin (Neoral) and tacrolimus. Liver Transpl. 8, 690-700 (2002).
111. Adigun, A. Q. et al. Effect of cirrhosis and liver transplantation on the gender difference in QT interval. Am. J. Cardiol. 95, 691-694 (2005).
112. Henriksen, J. H., Bendtsen, F., Hansen, E. F. & Møller, S. Acute non-selective β-adrenergic blockade reduces prolonged frequency-adjusted QT interval (QTc) in patients with cirrhosis. J. Hepatol. 40, 239-246 (2004).
113. Zambruni, A. et al. Effect of chronic β-blockade on QT interval in patients with liver cirrhosis. J. Hepatol. 48, 415-421 (2008).
114. Serste, T. et al. Deleterious effects of β-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 52, 1017-1022 (2010).
115. Pozzi, M. et al. Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child A cirrhosis. Am. J. Gastroenterol. 100, 1110-1116 (2005).
116. Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341, 709-717 (1999).